Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC).

González-Angulo, Ana M.; Green, M. C.; Murray, James L.; Palla, Shana L.; Koenig, KB; Brewster, A. M.; Valero, Vicente; Ibrahim, NK; Moulder, Stacy L.; Litton, Jennifer K.; Crawford, Donna; Flores, P. R.; Dryden, M. J.; Symmans, W. Fraser; Giordano, S.; Pusztai, Lajos; Buzdar, Aman U.; Mills, Gordon B.; Hortobágyi, G. N.; Meric‐Bernstam, Funda

doi:10.1200/jco.2011.29.15_suppl.1016

Cited by 25 publications

(26 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Three studies were conducted on hormone receptor (HR) positive metastatic breast cancer patients [10,12,28], and three studies were conducted in a HER2-positive metastatic setting [15,20,21], while in six studies the distinction between subtypes of breast cancer patients was not made [13,17,25,27,31,32]. None of the studies reported results regarding OS [10,12,13,15,17,[20][21][22][23][24][25][26][27][28][31][32][33]. All studies reported detailed outcomes pertaining to efficacy and/or safety [10,12,13,15,17,[20][21][22][23][24][25][26][27][28][31][32][33].…”

Section: Resultsmentioning

confidence: 92%

“…There were 16 studies evaluating everolimus (1492 patients, 17 articles; one study was described in two distinct articles [22,24]) [10,12,13,15,17,[20][21][22][23][24][25][26][27][28][31][32][33]. Ten studies described the results of phase I trials [13,17,[20][21][22][23]27,28,31,32], one described those of a phase I/II trial [15], four studies involved a phase II design [10,25,26,33] and one study involved a phase III design [12].…”

Section: Resultsmentioning

confidence: 97%

“…Ten studies described the results of phase I trials [13,17,[20][21][22][23]27,28,31,32], one described those of a phase I/II trial [15], four studies involved a phase II design [10,25,26,33] and one study involved a phase III design [12]. Four studies were conducted in the neo-adjuvant setting [22,23,26,33], while all the others dealt with recurrent, metastatic or refractory disease patients [10,12,13,15,17,20,21,25,27,28,31,32]. Three studies were conducted on hormone receptor (HR) positive metastatic breast cancer patients [10,12,28], and three studies were conducted in a HER2-positive metastatic setting [15,20,21], while in six studies the distinction between subtypes of breast cancer patients was not made [13,17,25,27,31,32].…”

Section: Resultsmentioning

confidence: 99%

“…Of these articles, 457 were irrelevant, 73 were reviews and 21 were finally eligible . After searching the references of all reviews and remaining articles, seven additional conference abstracts/articles were also included [31][32][33][34][35][36][37]. Overall, 28 articles were eligible for the systematic review [30][31][32][33][34][35][36][37].…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

mTOR inhibitors in breast cancer: A systematic review

Zagouri

Sergentanis

Chrysikos

et al. 2012

Gynecologic Oncology

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 92%

Section: Resultsmentioning

confidence: 97%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

mTOR inhibitors in breast cancer: A systematic review

Zagouri

Sergentanis

Chrysikos

et al. 2012

Gynecologic Oncology

View full text Add to dashboard Cite

“…Хотя начальные клинические результаты ис-следования эверолимуса и паклитаксела были обнадеживающими [35,37], рандомизирован-ное исследование II фазы неоадъювантного лечения базальноподобного РМЖ показало, что комбинация эверолимуса со стандартной химиотерапией значительно не улучшила па-тологический полный ответ [37].…”

Section: Wwwmalignanttumorsorg журнал «злокачественные опухоли»unclassified

Triple negative breast cancer: current status of the problem and unusual case of treatment

Муфазалов¹,

Шарипова²

2015

Zlokač. opuholi

View full text Add to dashboard Cite

Тройной негативный рак молочной железы: современное состояние проблемы и не совсем обычный случай лечения МУФАЗАЛОВ Ф.Ф., ШАРИПОВА Н.С.В статье представлен обзор литературных данных о клинических исследованиях, посвященных лечению тройного негативного рака молочной железы (ТНРМЖ), рассматривается активность существующих таргетных и химиопре-паратов. Описан не совсем обычный случай клинического течения и лечения ТНРМЖ.The article presents a review of clinical trials of treatment the triple negative breast cancer (TNBC). It considered the activity of existing target agents and chemotherapy. Described is not an ordinary case of the clinical course and treatment of TNBC.Ключевые слова: тройной негативный рак молочной железы, клинический случай. Контактная информация:Муфазалов Фагим Фанисович -заместитель главного врача по радиологии, доктор медицинских наук, профессор, главный радиолог МЗ Республики Башкортостан, вице-президент Российской Ассоциации терапевтических радиационных онкологов (РАТРО). ГБУЗ «Республиканский клинический онкологический диспансер» МЗ республики Башкортостан, г. Уфа. Шарипова Наиля Саматовна -врач-радиолог ГБУЗ «Республиканский клинический онкологический диспансер» МЗ республики Башкортостан, г. Уфа,

show abstract

Everolimus: Targeted Therapy on the Horizon for the Treatment of Breast Cancer

Barnett

2012

Pharmacotherapy

View full text Add to dashboard Cite

The mammalian target of rapamycin (mTOR) is a signaling kinase of the phosphatidylinositol 3-kinase/protein kinase B (also known as Akt) signaling pathway that mediates cell growth and metabolism. Dysregulation of the mTOR pathway creates a favorable environment for the development and progression of many cancers, including breast cancer, and is associated with the development of resistance to endocrine therapy and to the anti-human epidermal growth factor receptor-2 (HER2) monoclonal antibody trastuzumab. Therefore, the addition of mTOR inhibitors to conventional breast cancer therapy has the potential to enhance therapeutic efficacy and/or overcome innate or acquired resistance. Everolimus, an mTOR inhibitor with demonstrated preclinical activity against breast cancer cell lines, has been shown to reverse Akt-induced resistance to hormonal therapy and trastuzumab. Phase I-II clinical trials have demonstrated that everolimus has promising clinical activity in women with HER2-positive, HER2-negative, and estrogen receptor-positive breast cancer when combined with HER2-targeted therapy, cytotoxic chemotherapy, and hormonal therapy, respectively. Everolimus is generally well tolerated; hematologic abnormalities and stomatitis are most common adverse events when this drug is combined with cytotoxic chemotherapy. Based on these promising results, everolimus is currently under evaluation in a series of phase III Breast Cancer Trials of Oral Everolimus (BOLERO) trials of women with HER2-positive and estrogen receptor-positive breast cancer. Results of these trials will help to establish the role of everolimus in the treatment of clinically important breast cancer subtypes.

show abstract

Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC).

Cited by 25 publications

References 0 publications

mTOR inhibitors in breast cancer: A systematic review

mTOR inhibitors in breast cancer: A systematic review

Triple negative breast cancer: current status of the problem and unusual case of treatment

Everolimus: Targeted Therapy on the Horizon for the Treatment of Breast Cancer

Contact Info

Product

Resources

About